Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure

Journal of Clinical Virology

Volumn 47, Issue 1, 2010, Pages 79-81

  Stegmann, Sophie ^a,b   Manea, Maria Elena ^a   Charpentier, Charlotte ^a,b   Damond, Florence ^c   Karmochkine, Marina ^a   Laureillard, Didier ^a   Si Mohamed, Ali ^a   Weiss, Laurence ^a,b   Piketty, Christophe ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Foscarnet; HIV 2; Salvage therapy

Indexed keywords

ABACAVIR; DARUNAVIR; ETRAVIRINE; FOSCARNET; LAMIVUDINE; LOPINAVIR; MARAVIROC; RALTEGRAVIR; RITONAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE; VIRUS LOAD;

FOSCARNET; HIV INFECTIONS; HIV-2; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SALVAGE THERAPY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 72049095343     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.11.008     Document Type: Article

References (17)

1. Hizi A., Tal R., and Hughes S.H. Mutational analysis of the DNA polymerase and ribonuclease H activities of human immunodeficiency virus type 2 reverse transcriptase expressed in Escherichia coli. Virology 180 (1991) 339-346
2. Witvrouw M., Pannecouque C., Van Laethem K., Desmyter J., De Clercq E., and Vandamme A.M. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. Aids 13 (1999) 1477-1483
3. Witvrouw M., Pannecouque C., Switzer W.M., Folks T.M., De Clercq E., and Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 9 (2004) 57-65
4. Desbois D., Roquebert B., Peytavin G., Damond F., Collin G., Benard A., et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 52 (2008) 1545-1548
5. Roquebert B., Damond F., Collin G., Matheron S., Peytavin G., Benard A., et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 62 (2008) 914-920
6. Andries K., Azijn H., Thielemans T., Ludovici D., Kukla M., Heeres J., et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 48 (2004) 4680-6
7. Meyer P.R., Matsuura S.E., Zonarich D., Chopra R.R., Pendarvis E., Bazmi H.Z., et al. Relationship between 3′-azido-3′-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 77 (2003) 6127-6137
8. Vrang L., Oberg B., Lower J., and Kurth R. Reverse transcriptases from human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIVMAC) are susceptible to inhibition by foscarnet and 3′-azido-3′-deoxythymidine triphosphate. Antimicrob Agents Chemother 32 (1988) 1733-1734
9. Mathiesen S., Roge B.T., Weis N., Lundgren J.D., Obel N., and Gerstoft J. Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations. Aids 18 (2004) 1076-1078
10. Canestri A., Ghosn J., Wirden M., Marguet F., Ktorza N., Boubezari I., et al. Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance. Antivir Ther 11 (2006) 561-566
11. Charpentier C., Laureillard D., Sodqi M., Si-Mohamed A., Karmochkine M., Belec L., et al. Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients. J Clin Virol 43 (2008) 212-215
12. Damond F., Collin G., Descamps D., Matheron S., Pueyo S., Taieb A., et al. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J Clin Microbiol 43 (2005) 4234-4236
13. Schim van der Loeff M.F., and Aaby P. Towards a better understanding of the epidemiology of HIV-2. Aids 13 Suppl A (1999) S69-84
14. Markovitz D.M. Infection with the human immunodeficiency virus type 2. Ann Intern Med 118 (1993) 211-218
15. Eron J.J., Benoit S.L., Jemsek J., MacArthur R.D., Santana J., Quinn J.B., et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 333 (1995) 1662-1669
16. Katlama C., Ingrand D., Loveday C., Clumeck N., Mallolas J., Staszewski S., et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 276 (1996) 118-125
17. Gray G., Violari A., McIntyre J., Jivkov B., Schnittman S., Reynolds L., et al. Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: its role in preventing HIV infection in infants. J Acquir Immune Defic Syndr 42 (2006) 169-176